Latran, 2 mg/ml 4 ml 5 pcs

• prevention, prevention and elimination of nausea and vomiting in the postoperative period;
• symptomatic treatment of alcohol withdrawal syndrome (especially of mild to moderate severity).
• Nausea and vomiting caused by x-ray, radio- or chemotherapy with anticancer drugs or exposure to ionizing radiation;

.

Active ingredient

Composition

Active substance:

ondansetron hydrochloride dihydrate (in terms of base) 2 mg;

Auxiliary substances:

Sodium chloride;

Hydrochloric acid;

Water for injection;

How to take, the dosage

Intravenously, intramuscularly, orally.

Cytostatic therapy: The choice of dosing regimen is determined by the emetogenicity of the antitumor therapy. For adults, the daily dose is usually 8-32 mg; the following regimens are recommended:

In moderate emetogenic chemotherapy or radiotherapy

Highly emetogenic chemotherapy

Interaction

Because ondansetron is metabolized by the liver enzyme system (cytochrome P450), caution is required when used together:

– with enzymatic inducers of P450 (CYP2D6 and CYP3A) (barbiturates, carbamazepine, carisoprodol, glutethimide, griseofulvin, nitrous oxide, papaverine, phenylbutazone, phenytoin and probably other hydantoins, rifampicin, tolbutamide);

– with P450 enzyme inhibitors (CYP2D6 and CYP3A) (allopurinol, macrolide antibiotics, antidepressants – MAO inhibitors, chloramphenicol, cimetidine, estrogen-containing oral contraceptives, diltiazem, disulfiram, erythromycin, valproic acid, sodium valproate, fluconazole, fluoroquinolones, isoniazid, ketoconazole, lovastatin, metronidazole, omeprazole, propranololol, quinidine, quinine, verapamil).

Special Instructions

Patients with signs of bowel obstruction require regular monitoring after using the drug because ondansetron may cause constipation.

The infusion solution should be prepared immediately prior to use. If necessary, the prepared infusion solution may be stored for a maximum of 24 h at 2-8 °C prior to use.

The hypersensitivity reactions with Latran® may occur in patients previously observed for similar reactions with other selective 5-HT3 receptor antagonists.

At the time of infusion, protection from light is not required: the diluted injectable solution remains stable for at least 24 hours in natural light or normal light.

Contraindications

Side effects

Gastrointestinal organs: hiccups, dry mouth, diarrhea, constipation, sometimes asymptomatic transient increase in serum aminotransferases.

Allergic reactions: urticaria, bronchospasm, laryngospasm, angioedema, anaphylaxis.

Nervous system disorders: headache, dizziness, spontaneous motor disorders and seizures.

Cardiovascular system: chest pain, in some cases with ST-segment depression, bradycardia, arrhythmias, arterial hypotension.

Others: local reactions (pain, burning and redness at the injection site), blood rush to the face, fever, temporary visual acuity impairment, hypokalemia.

Overdose

In cases of suspected overdose, symptomatic therapy is indicated.

In cases of overdose, the use of ipecacuana is not recommended, as it is unlikely that this drug will be effective during the anti-emetic effect of Latran®.

A specific antidote is not known.

Similarities